OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Evangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 10, pp. 1300-1308
Open Access | Times Cited: 16
Evangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 10, pp. 1300-1308
Open Access | Times Cited: 16
Showing 16 citing articles:
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
Steven P. Treon, Camille N. Kotton, Jae‐Hyun Park, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Steven P. Treon, Camille N. Kotton, Jae‐Hyun Park, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 17
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 17
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Alessandro Campanella, A Capasso, Silvia Heltai, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 745-750
Open Access | Times Cited: 4
Alessandro Campanella, A Capasso, Silvia Heltai, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 745-750
Open Access | Times Cited: 4
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms
Moraima Jiménez, Candela Fernández‐Naval, Vı́ctor Navarro, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1204-1213
Closed Access | Times Cited: 7
Moraima Jiménez, Candela Fernández‐Naval, Vı́ctor Navarro, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1204-1213
Closed Access | Times Cited: 7
Covid-19 in patients with haematological malignancies
Hubert Warda, Katarzyna Skórka, Krzysztof Giannopoulos
Acta Haematologica Polonica (2024) Vol. 55, Iss. 2, pp. 73-89
Open Access | Times Cited: 1
Hubert Warda, Katarzyna Skórka, Krzysztof Giannopoulos
Acta Haematologica Polonica (2024) Vol. 55, Iss. 2, pp. 73-89
Open Access | Times Cited: 1
The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review
SeyedAhmad SeyedAlinaghi, Mohsen Dashti, Arian Afzalian, et al.
Preventive Medicine Reports (2024) Vol. 44, pp. 102778-102778
Open Access | Times Cited: 1
SeyedAhmad SeyedAlinaghi, Mohsen Dashti, Arian Afzalian, et al.
Preventive Medicine Reports (2024) Vol. 44, pp. 102778-102778
Open Access | Times Cited: 1
Vaccination strategies for patients with lymphoma treated in early lines of therapies: a real-world practice survey among Fondazione Italiana Linfomi centers
Ombretta Annibali, Michele Merli, Carla Minoia, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 66, Iss. 1, pp. 109-114
Closed Access | Times Cited: 1
Ombretta Annibali, Michele Merli, Carla Minoia, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 66, Iss. 1, pp. 109-114
Closed Access | Times Cited: 1
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 524-524
Open Access | Times Cited: 3
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 524-524
Open Access | Times Cited: 3
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Evangelos Terpos, A.R. Branagan, Ramón García‐Sánz, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 107-112
Open Access | Times Cited: 3
Evangelos Terpos, A.R. Branagan, Ramón García‐Sánz, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 107-112
Open Access | Times Cited: 3
Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
Line Dam Heftdal, Sebastian Rask Hamm, Laura Pérez‐Alós, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 2, pp. 229-239
Open Access | Times Cited: 3
Line Dam Heftdal, Sebastian Rask Hamm, Laura Pérez‐Alós, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 2, pp. 229-239
Open Access | Times Cited: 3
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia
M Gambacorti Passerini, Tamar Ratishvili, Jonathon M. Monroe, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 4, pp. 874-883
Closed Access | Times Cited: 2
M Gambacorti Passerini, Tamar Ratishvili, Jonathon M. Monroe, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 4, pp. 874-883
Closed Access | Times Cited: 2
Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination
Yu Nakagama, SungGi Chi, Yosuke Minami, et al.
Journal of Infection and Chemotherapy (2022) Vol. 29, Iss. 1, pp. 112-114
Open Access | Times Cited: 2
Yu Nakagama, SungGi Chi, Yosuke Minami, et al.
Journal of Infection and Chemotherapy (2022) Vol. 29, Iss. 1, pp. 112-114
Open Access | Times Cited: 2
